otc: wuhn · add/adhd ptsd bi-polar pms source: world health organization / cdc 2017-2019 3 of 5...

© Wuhan General Group Inc – 2020

6500 TransCanada Hwy, Suite 400, Pte-Claire, Qc, H9R 0A5, Canada

www.wuhn.org | [email protected]

APRIL 2020

At the forefront of nutraceutical medicinal cannabis and mushrooms research, formulations and delivery systems.

OTC: WUHN

http://www.wuhn.org/

2APRIL 2020 OTC | WUHN

In addition to historical information, this corporate release may contain statements that constitute forward-looking statements

within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities

Litigation Reform Act of 1995.

Forward-looking statements contained in this corporate release include the intent, belief, or expectations of the Company and

members of its management team with respect to the Company's future business operations and the assumptions upon which such

statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future

performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such

forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete

anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance,

efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or

performance of the Company's business units or the market price of its common stock. Additional factors that would cause actual

results to differ materially from those contemplated within this corporate release can also be found on the Company's website. The

Company disclaims any responsibility to update any forward-looking statements.

DISCLAIMER

PRESENTATIONAGENDA

Background

& Opportunity

About Wuhan

& Portfolio

Business Outlook

& Management Team

Industry Support

& Key Takeaways

Connect

With Us

01

02

03

04

05

BACKGROUND& OPPORTUNITY

01


THE INVESTMENT OPPORTUNITYCosmetics and food for special medical purposes (FSMP) company with cannabinoid and psilocybin research, formulation and

delivery system divisions.

$33 Million net first year

“IT IS TIME WE GET BACK TO OUR

ROOTS. RESEARCH HAS PROVEN THE

BENEFITS OF NATURE’S PLANT-BASED

MEDICINES, MAGIC MUSHROOMS AND

CANNABIS, THEIR ACTIVE INGREDIENTS

– PSILOCYBIN AND CANNABINOIDS.”

DR. ANNA MORERA LERALTA

DOCTOR IN MEDICINE AND SURGERY,

VALL D’HEBRON HOSPITAL, UNIVERSITY OF BARCELONA


MENTAL HEALTHA MONUMENTAL PROBLEM

≈ 31%OF GLOBAL

POPULATION WITH A MENTAL DISORDER

The number of patients diagnosed with mental health disorders in 2017.

Source: World Health Organization / Our World in Data 2017

0 200 400 600 800 1000

Eating disorders

Schizophrenia

Bipolar disorder

Drug addiction

Treatment-resistant depression (TRD)

Alcohol addiction

Anxiety disorders

Major depressive disorder (MDD)

PTSD and/or MDD

Any mental or substance addiction

Numbers of Patients (millions)


CHRONIC AND INFLAMMATORY ILLNESSESEPICENTER OF DISEASESList of chronic and inflammatory diseases and their worldwide statistics:

CancerDiabetesEpilepsy

Crohn’s diseaseArthritis

InflammationPneumonia

IBSAsthma

Fibromyalgia

GlaucomaMultiple Sclerosis (MS)

AnxietyDepressionMigraines

Muscle SpasmsADD/ADHD

PTSDBi-polar

PMS

Source: World Health Organization / CDC 2017-2019

3 OF 5PEOPLE DIE DUE TO

CHRONIC INFLAMMATORY

DISEASES

305MPEOPLE

AFFECTEDWORLDWIDE

396CASES PER 100,000 GLOBALLY SUFFERINFLAMMATORY BOWEL DISEASE

(IBD)

Stroke, chronic respiratory

diseases, heart disorders,

cancer, obesity, and diabetes.

Arthritis and joint diseases.IBS, ulcerative colitis,

Crohn’s diseases.


“THE POTENTIAL THERAPEUTIC BENEFITS

OF PSILOCYBIN-ASSISTED THERAPY ARE

REAL, AND OF POTENTIAL MEDICAL AND

PUBLIC HEALTH SIGNIFICANCE.”

MATTHEW JOHNSON,

JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

PROFESSORS OF PSYCHIATRY

MAGIC MUSHROOM – PSILOCYBINUNEXPLORED FUNGI TO TREAT MENTAL ILLNESSESFDA granted "breakthrough therapy" status to psilocybin in 2020. Acknowledgement that Major Depressive Disorder (MDD)

represents an unmet medical need and suggests that psilocybin may offer a substantial clinical improvement over existing

therapies.


STEVEN R. PATIERNO, PHD,

DEPUTY DIRECTOR OF THE DUKE CANCER INSTITUTE AND

PROFESSOR OF MEDICINE AT DUKE UNIVERSITY SCHOOL OF MEDICINE

“DISEASES, SUCH AS ANOREXIA, INFLAMMATION,

PNEUMONIA, MULTIPLE SCLEROSIS,

NEURODEGENERATIVE DISORDERS, EPILEPSY,

GLAUCOMA, OSTEOPOROSIS, SCHIZOPHRENIA,

CARDIOVASCULAR DISORDERS, CANCER, AND

METABOLIC SYNDROME-RELATED DISORDERS,

ARE BEING TREATED OR HAVE THE POTENTIAL TO

BE TREATED BY CANNABINOIDS.”

RAPHAEL MECHOULAM

MEDICINAL CHEMISTRY AND NATURAL PRODUCTS DEPT, PHARMACY SCHOOL,

THE HEBREW UNIVERSITY OF JERUSALEM, ISRAEL

CANNABIS – CANNABINOIDSMIRACLE PLANT TO TREAT MANY HEALTH CONDITIONSCannabinoids are commonly used to treat seizure disorder, anxiety, pneumonia, dystonia (a muscle disorder), Parkinson disease,

Crohn disease, and many other conditions.


POTENTIAL COST SAVINGS FROM PSYCHEDELIC-ASSISTED THERAPIES

$198B

US & EUMENTAL HEALTH

COSTS

$402B

NEW REDUCED US & EU COSTS

$204B

TREATMENTS WITH PSILOCYBIN

US & EU POTENTIAL

SAVINGS

Source: Prohibition Partners, US Department of Health et al. 2017


“THE GLOBAL

MEDICAL CANNABIS

MARKET SIZE IS

PROJECTED TO REACH

$97.35B USD BY THE

END OF 2026.”

Fortune Business Insights™

THE GLOBAL MEDICAL CANNABIS MARKETThe market will exhibit a CAGR of 32.92% during the forecast period, 2019-2026.


“THE INTRODUCTION OF SMOKELESS

CANNABIS IN DOSAGE FORM WILL

IMMEDIATELY EASE HUMAN PAIN AND

SUFFERING AND HELP TO MOVE MEDICAL

MARIJUANA FROM THE UNDERGROUND

ECONOMY TO THE MAINSTREAM OF THE

NATION’S HEALTH-CARE SYSTEM.”

STEVEN R. PATIERNO, PHD,

DEPUTY DIRECTOR OF THE DUKE CANCER INSTITUTE AND

PROFESSOR OF MEDICINE AT DUKE UNIVERSITY SCHOOL OF MEDICINE

WHAT CAN CBD TREAT?CBD has been identified as a remedy for many health conditions.

Source: HelloMD Medicinal Marijuana 1400 Patient Survey Results 2016

0 200 400 600

Anxiety

Pain

Stress

Back pain

Insomnia

Depression

Migraines

Arthritis

Inflammation

Muscle Spasms

Loss of appetite

ADD/ADHD

Nausea

PTSD

Bi-polar

Asthma

PMS

Loss of Libido

Fibromyalgia

Cancer

Diabetes

Menopause

Anorexia

Crohn’s disease

Number of Survey Respondents

MEDICINAL CANNABIS USE CASES

ABOUT WUHAN& PORTFOLIO

02


VISION, MISSION & CORE VALUESIn our journey form seed to shelf and spore to store, we are guided by the following principles.

OUR VISION

Our vision is to improve people’s quality of life by unleashing

the full potential of medicinal cannabis and mushrooms.

OUR MISSION

Our mission is to be a global leader in medicinal cannabis and mushrooms. From seed to

shelf and spore to store, we are driven by a passion for medicine, science and technology.

OUR CORE VALUES

Quality. Science. Traceability.

Humility. Accountability. Excellence.


OUR PILLARSBringing innovative therapies to life.

From seed to shelf.

MEDICINAL CANNABIS

From spore to store.

MEDICINAL MUSHROOMS

And everything

in between.

SCIENCE & DATA


SCIENTIFIC RESEARCHAt the core of our business we are focusing on the science and research behind medicinal cannabis and medicinal mushrooms.

DRUG TARGET DISCOVERY

PRE-CLINICAL TRIALS

CLINICAL TRIALS FDA APPROVAL & COMMERCIALIZA

TION


OUR PORTFOLIO

Medspresso™ is founded on the philosophy of combining health benefits

with our three E’s : Extraordinary, Exquisite and Elegant. All of our

premium beverages are served in environmentally friendly packaging.

Doctor Anna Morera Leralta and her team of molecular research

scientists have created the ultimate CBD-infused beauty and health line.

Dr. AnnaRx™ products are formulated with pharmaceutical premium

grade CBD, all-natural ingredients and are gender neutral.

M2BIO is researching and developing indications for psilocybin new

therapies, through clinical trials, that will help patients who suffer from

mental illness, addiction, Alzheimer’s and Parkinson’s.


An exclusive line of CBD infused beverages in biodegradable capsule format:

- Tanzanian Peaberry Coffee, Ivory Coast Hot Chocolate, and Cederberg Rooibos Tea.


Cosmetics and food for special medical purposes (FSMP).


Q1 2020Concluded in vivo and

in vitro testing

Q4 2020Start Phase 1Human Trial

Q2 2020Pre-enrolment

Patient-screening

Q3 2020Provisional patent for method

and delivery of psilocybin to treat alcoholism

Schedule I Drugs (Psychedelics) Psilocybin. Developing indications for new therapies that will help patients who suffer

from mental disorders, addiction, Alzheimer's and Parkinson’s.

BUSINESS OUTLOOK& MANAGEMENT TEAM

03


SUCCESS FORMULADetermination, Dedication, Discipline, Diversity and Direction.

SUCCESS FORMULA

DISTRIBUTION CHANNEL

Unique relationships are paving the

way for international distribution.

LOCATION

Attaining competitive advantages

with key strategic locations in

South Africa, UK and Canada.

OPPORTUNITIES

Cannabis and psilocybin embody

significant medical and health benefits,

as well as enormous commercial upside.

KEY PARTNERSHIPS

Fostering exceptional partnerships with

academic and research institutes.


BUSINESS MODEL - MEDICATIONResearch and discovering new treatment and cures for a range of illnesses.

From seed to shelf

MEDICINAL CANNABIS

From spore to store

MEDICINAL MUSHROOMS

RESEARCH, TRIALS & DATA ANALYSIS

FDA APPROVED MEDICATION & NUTRACEUTICAL SUPPLEMENT

$65BPROJECTED

ADRESSABLE MARKET 2022


BUSINESS MODEL – NUTRACEUTICALSDeveloping innovative food for special medical purposes.

100,000STORES

ACROSS US AND SOUTH AFRICA

$33MFIRST YEAR

REVENUE

≈$6AVERAGE PRICE

PER UNIT


BUSINESS MODEL – COSMETICSDeveloping state-of-the-art cannabinoid infused cosmetics.

50,000STORES

ACROSS US AND SOUTH AFRICA

$52MFIRST YEAR

REVENUE

≈$35AVERAGE PRICE

PER UNIT


THE TEAM

Jeff RobinsonChief Executive Officer

Dr. Anna Morera LeraltaChief Medical Officer

Luka MarjanovicHead of Product

Ramy KamanehConsultant


PR UDLY MADE

IN SOUTH

AFRICA

KEY STRATEGIC PARTNERSHIPS AND SUPPLIERSWuhan is highly committed to partnering with exemplary medical and scientific research institutions globally.


COMPARABLES

COMPASS Pathways Limited

• Developing synthetic psilocybin

therapies.

• Currently in Phase 2(b) trial for

treatment resistant depression.

• Seed Financing (2017): $19.45M

• Series A (2018): $100.39M USD.

• Private. Market Cap: ≈ 800M USD

Mind Medicine Inc.

• Neuro-pharmaceutical company.

• Trading on the NEO, ticker MMED.

• Licensed 18-MC, a form of ibogaine, for

treatment of opioid addiction.

• Commencing Phase 2 trials.

• Private placement pre-IPO: $17M USD.

• Market Cap: $105M USD.


COMPARABLES

Wuhan General Group

• Cosmetics and FSMP company with

cannabinoid and psilocybin research,

formulation and delivery system divisions.

• Trading on the OTC, ticker WUHN.

• Currently in Pre-enrolment Patient-

screening for Phase 1 Human trial.

• Market Cap: $2.5M USD

Champignon Brands

• Mushroom health supplements firm.

• Trading on the CSE, ticker SHRM.

• Flagship brand, Vitality Super Teas.

• Recent acquisitions of important IP

around ketamine delivery systems.

• IPO in February 2020 $2.9M.

• Market Cap: $71M USD.


COMPARABLES OVERVIEW

MIND MEDICINECOMPASS

PATHWAYSCHAMPIGNON

BRANDSWUHAN

GENERAL GROUP

Market Cap* US $105M Private: ≈ $800M US $71M US $2.5M

Clinical Trials Yes Yes Yes Yes

Clinical Trial Progress

Phase II Phase II Phase I Phase I

Drug Ibogaine & LSD PsilocybinKetamine & Psilocybin

Psilocybin & Cannabinoids

* Market capitalization as of April 15th, 2020.

INDUSTRY SUPPORT& KEY TAKEAWAYS

04


“RECENT STUDIES ARE FINDING THAT

DRUGS SUCH AS LSD AND PSILOCYBIN

CAN HELP TO ALLEVIATE DEPRESSION,

ANXIETY AND ADDICTION.”

- Wall Street Journal 2020

“PSYCHEDELIC EVENTS ARE GOING

MAINSTREAM, WHERE THE MUCH-

MALIGNED MUSHROOM INDUSTRY

FOCUSES ON MENTAL HEALTH.”

- Forbes 2020

PSYCHEDELICS

“AMERICA’S FOOD AND DRUG ADMINISTRATION

HAS GIVEN ’BREAKTHROUGH’ STATUS TO

PSILOCYBIN TRIALS.”

-The Economist 2019


CANNABINOIDS

Sold 6$ per products

on average

“WE HAVE BEEN TERRIBLY AND

SYSTEMATICALLY MISLED FOR NEARLY 70

YEARS IN REGARD TO CANNABIS. I AM

CONVINCED THAT IT IS IRRESPONSIBLE TO NOT

PROVIDE THE BEST CARE WE CAN, CARE THAT

OFTEN INVOLVES MARIJUANA.

I AM NOT BACKING DOWN ON MEDICAL

MARIJUANA; I AM DOUBLING DOWN.”

DR. SANJAY GUPTA

AMERICAN NEUROSURGEON, CNN


KEY TAKEAWAYSNew emerging market opportunity – High margin pharmaceutical and nutraceutical research, manufacturing and distribution.

FIRST IN MARKET TO RESEARCH PSILOCYBIN FOR TREATMENT OF ALCOHOLISM AND CARDIOVASCULAR TISSUE.

ESTABLISHED DISTRIBUTION CHANNELS IN THE US, CANADA, EUROPE AND AFRICA.

EARLY STAGE ENTRY INTO CANNABINOID AND PSILOCYBINCOMPANY – FIRST ROUND OF FINANCING – ENORMOUS UPSIDE.

RESEARCHING UNDISCOVERED PROPERTIES OF CANNABINOIDS FOR TREATMENT OF RESPIRATORY INFECTIOUS DISEASES.

LOCATIONS& CONNECT WITH US

05


3

1

2

LOCATIONSMONTREAL | LONDON | CAPE TOWN

CONNECT WITH US!

Don’t forget to stay in touch and share your experiences and ideas!

(034) 600 11 57 89

[email protected]

Contact us:

facebook.com/DrAnnaRx

@DrAnnaRx

@DrAnnaRx

Follow Dr. AnnaRx™ on:

www.wuhn.org

facebook.com/WUHN

@WGG_Company facebook.com/Medspresso

@Medspresso

@Medspresso.Official

Follow Medspresso™ on:

www.drannarx.com www.medspresso.store

otc: wuhn · add/adhd ptsd bi-polar pms source: world health organization / cdc 2017-2019 3 of 5...

Documents